Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1993-04-06
1995-06-20
Wityshyn, Michael G.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 21, 530384, 530848, A61K 3542, C07K 1506
Patent
active
054260973
ABSTRACT:
The subject invention provides a pharmaceutical composition, which comprises an amount of calreticulin effective for blocking or preventing thrombosis in a subject, causing substantially no defect or no defect in normal hemostasis, and a pharmaceutically effective carrier. The subject invention provides a method for blocking or preventing thrombosis in a subject, causing substantially no defect or no defect in normal hemostasis, which method comprises administering calreticulin to the subject in an amount effective for blocking or preventing thrombosis. The subject invention provides a pharmaceutical composition, which comprises calreticulin in combination with an other antithrombotic agent, in an amount and proportion effective for enhancing the action of the other antithrombotic agent, to prevent clotting or dissolve clots which have already formed. The subject invention provides a method for enhancing the action of an other antithrombotic agent which prevent clotting or dissolve clots which have already formed, comprising administering to a subject calreticulin in combination with the other antithrombotic agent in an amount and proportion for enhancing the action of the other antithrombotic agent, to prevent clotting or dissolve clots which have already formed.
REFERENCES:
Sueyoshi, Tatsuya et al., "A new procedure for the separation of protein 2 . . . ", Thrombosis Research, vol. 63, pp. 569-575, 1991.
Abe Hiroshi et al., Molecular Brain Research, vol. 14 pp. 337-343 (1992).
Johnson Robin et al., Molecular Brain Research, vol. 12, pp. 69-76, (1992).
Opas, Michal et al., "Calcium Storage in non-muscle tissue . . . ", Biochem. Cell Biol., vol. 70, pp. 972-979 (1992).
Routsias, J. A. et al, "Calreticulin . . . ", Clin. Exp. Immunol., vol. 91(3), pp. 437-441 (1993) CA119(19):2015996.
Baksh, Shairaz et al., "Expression and purification of recombinant and native calrehiculin," Protein Expression Purification, vol. 3(4), pp. 322-331 (1992). CA117(17):166922m.
Romson, et al., Thrombosis Research (Mar. 15, 1980) 17(6): 841-853.
Gitel, et al., PNAS-USA (Jul. 1977) 74(7): 3028-3032.
Benedict, et al., Circulation Research (Jan. 1986) 58(1): 58-67.
Bush, et al., Faseb J. (Oct. 1990) 4(13): 3087-3098.
Routsias, et al., Clin. Exp. Immunol. (Mar. 1993) 91(3): 437-441.
Benedict, et al., J. Clin. Invent. (Nov. 1991) 88: 1760-1765.
Mookerjee, et al., Immunol. Invest (1993) 22(6&7): 415-429.
Baksh, et al., Protein Express, and Purif. (Aug. 1992) 3(4): 322-331.
Michalak, et al., Biochem. J. (Aug. 1, 1992) 285(3): 681-692.
Fliegel, et al., J. Biol. Chem. (Dec. 25, 1989) 264(36): 21522-21528.
Benedict Claude
Kuwabara Keisuke
Ryan Jane
Stern David M.
Board of Regents , The University of Texas System
Sayala C.
The Trustees of Columbia University in the City of New York
White John P.
Wityshyn Michael G.
LandOfFree
Calreticulin: a novel antithrombotic agent does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Calreticulin: a novel antithrombotic agent, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Calreticulin: a novel antithrombotic agent will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1844222